Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs
Open Access
- 18 June 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325695
Abstract
Target trial emulation applies design principles from randomised controlled trials (RCTs) to the analysis of observational data, potentially replicating RCT results in real-world settings. The EPIC trial reported that pimobendan delays the onset of congestive heart failure (CHF) and extends survival in dogs with preclinical degenerative mitral valve disease (DMVD). The current study aimed to explore the extent to which target trial emulation approximates the EPIC trial results in a primary-care setting. Grade IV/VI murmur diagnosis was defined as the treatment intervention stage. There were 928 dogs ≥ 6 years and ≤ 15 kg at first grade IV/VI murmur diagnosis recorded from January 1, 2016, to December 31, 2018 in the VetCompass database included in the study. A causal inference “target trial emulation” approach using VetCompass anonymised clinical data was designed to replicate the EPIC trial with adaptation for a primary-care setting and to address immortal time bias, confounding bias and loss to follow-up. After bias adjustments to establish causal effects using observational data, the 5-year CHF cumulative incidence was lower in dogs prescribed pimobendan (34.1%, 95% CI 26.5–42.0) than dogs not prescribed pimobendan (56.3%, 95% CI 52.8–59.8). Dogs prescribed pimobendan had 311 fewer days of health lost to CHF (95% CI 224–395 days) within 5 years. Dogs prescribed pimobendan lived longer (adjusted mean survival time 1051 days, 95% CI 967–1125) than dogs not prescribed pimobendan (905 days, 95% CI 871–940 days). This study demonstrates that target trial emulation within veterinary research can replicate findings from RCTs. Clinically, the current findings suggest that preclinical grade IV murmur diagnosis may offer an appropriate intervention stage to begin pimobendan therapy in dogs with presumed DMVD.Keywords
Funding Information
- Dogs Trust (5654)
This publication has 35 references indexed in Scilit:
- The importance of considering competing risks in recurrence analysis of intracranial meningiomaJournal of Neuro-Oncology, 2024
- Trials using composite outcomes neglect the presence of competing risks: a methodological survey of cardiovascular studiesJournal of Clinical Epidemiology, 2023
- The Longitudinal Outcome Of Canine (K9) myxomatous mitral valve disease (LOOK-Mitral registry): Baseline characteristicsJournal of Veterinary Cardiology, 2021
- Estimation and modeling of the restricted mean time lost in the presence of competing risksStatistics in Medicine, 2021
- Murmur grading in humans and animals: past and presentJournal of Veterinary Cardiology, 2018
- Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJournal of Clinical Epidemiology, 2016
- Data Analysis2016
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studiesStatistics in Medicine, 2015
- Degenerative mitral valve disease: Survival of dogs attending primary-care practice in EnglandPreventive Veterinary Medicine, 2015
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006